a Department of Pharmaceutics and industrial pharmacy, Faculty of pharmacy , Cairo University , Cairo , Egypt.
Drug Deliv. 2018 Nov;25(1):1706-1717. doi: 10.1080/10717544.2018.1497107.
Keratomycosis is a serious corneal disease that can cause a permanent visual disability if not treated effectively. Sertaconazole nitrate (STZ), a novel broad spectrum antifungal drug, was suggested as a promising treatment. However, its utility in the ocular route is restricted by its poor solubility, along with other problems facing the ocular delivery like short residence time, and the existing corneal barrier. Therefore, the objective of this study was to formulate STZ loaded binary mixed micelles (STZ-MMs) enriched with different penetration enhancers using thin-film hydration method, based on a 3.2 mixed factorial design. Different formulation variables were examined, namely, type of auxiliary surfactant, type of penetration enhancer, and total surfactants: drug ratio, and their effects on the solubility of STZ in MMs (S), particle size (PS), polydispersity index (PDI), and zeta potential (ZP) were evaluated. STZ-MMs enhanced STZ aqueous solubility up to 338.82-fold compared to free STZ. Two optimized formulations (MM-8 and MM-11) based on the desirability factor (0.891 and 0.866) were selected by Design expert software for further investigations. The optimized formulations were imaged by TEM which revealed nanosized spherical micelles. Moreover, they were examined for corneal mucoadhesion, stability upon dilution, storage effect, and ex vivo corneal permeation studies. Finally, both in vivo corneal uptake and in vivo corneal tolerance were investigated. MM-8 showed superiority in the ex vivo and in vivo permeation studies when compared to the STZ-suspension. The obtained results suggest that the aforementioned STZ loaded mixed micellar system could be an effective candidate for Keratomycosis-targeted therapy.
曲霉菌病是一种严重的角膜疾病,如果不能有效治疗,可能会导致永久性视力障碍。硝酸舍他康唑(STZ)是一种新型广谱抗真菌药物,被认为是一种有前途的治疗方法。然而,由于其溶解度差,以及眼部给药所面临的其他问题,如停留时间短和现有的角膜屏障,其在眼部途径的应用受到限制。因此,本研究的目的是通过薄膜水化法,基于 3.2 混合析因设计,用不同的渗透增强剂来制备 STZ 负载的二元混合胶束(STZ-MMs)。考察了不同的制剂变量,即辅助表面活性剂的类型、渗透增强剂的类型、总表面活性剂:药物的比例,并评估了它们对 STZ 在 MM 中的溶解度(S)、粒径(PS)、多分散指数(PDI)和 Zeta 电位(ZP)的影响。与游离 STZ 相比,STZ-MMs 使 STZ 的水溶解度提高了 338.82 倍。通过 Design expert 软件选择基于理想因子(0.891 和 0.866)的两个优化配方(MM-8 和 MM-11)进行进一步研究。优化后的配方通过 TEM 成像,显示出纳米级球形胶束。此外,还对其进行了角膜黏附性、稀释稳定性、储存效应和体外角膜渗透研究。最后,研究了体内角膜摄取和体内角膜耐受性。与 STZ 混悬剂相比,MM-8 在体外和体内渗透研究中表现出优越性。研究结果表明,上述 STZ 负载混合胶束系统可能是一种针对曲霉菌病的有效治疗候选药物。
Front Bioeng Biotechnol. 2023-8-4
Pharmaceuticals (Basel). 2023-6-10
AAPS PharmSciTech. 2023-2-14